Treatment options for recurrent glioblastoma: pitfalls and future trends

References

• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the postirradiation period. J. Neurosurg.50, 624–628 (1979).
   PubMed Web of Science ®Google Scholar
• Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int. J. Radiat. Oncol. Biol. Phys.6, 1215–1228 (1980).
   PubMed Web of Science ®Google Scholar
• Burger PC, Dubois PJ, Schold SC Jr et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J. Neurosurg.58, 159–169 (1983).
   PubMed Web of Science ®Google Scholar
• Dooms GC, Hecht S, Brant-Zawadzki M et al. Brain radiation lesions: MR imaging. Radiology158, 149–155 (1986).
   PubMed Web of Science ®Google Scholar
• Tihan T, Barletta J, Parney I et al. Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum. Pathol.37, 272–282 (2006).
   PubMed Web of Science ®Google Scholar
• Rock JP, Scarpace L, Hearshen D et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery54, 1111–1117 (2004).
   PubMed Web of Science ®Google Scholar
• Tsuyuguchi N, Takami T, Sunada I et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery – in malignant glioma. Ann. Nucl. Med.18, 291–296 (2004).
   PubMed Web of Science ®Google Scholar
• Rachinger W, Goetz C, Popperl G et al. Positron emission tomography with O-(2-18Ffluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery57, 505–511 (2005).
   PubMed Web of Science ®Google Scholar
• de Wit MC, de Bruin HG, Eijkenboom W et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology63, 535–537 (2004).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ, Chalmers L et al. Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma. J. Neurooncol.82(1), 81–83 (2006).
   PubMedGoogle Scholar
• Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer113, 405–410 (2008).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Tosoni A et al.MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol.26, 2192–2197 (2008).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Spagnolli F et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro. Oncol.10(3), 361–367 (2008).
   PubMed Web of Science ®Google Scholar
• Brandsma D, Stalpers L, Taal W et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol.9, 453–461 (2008).
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet345, 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Young B, Oldfield EH, Markesbery WR et al. Reoperation for glioblastoma. J. Neurosurg.55, 917–921 (1981).
   PubMed Web of Science ®Google Scholar
• Barker FG 2nd, Chang SM, Gutin PH et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery42, 709–720 (1998).
   PubMed Web of Science ®Google Scholar
• Nieder C, Adam M, Molls M, Grosu AL. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit. Rev. Oncol. Hematol.60, 181–193 (2006).
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol.8, 1277–1280 (1990).
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17, 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Ballman KV, Buckner JC, Brown PD et al. The relationship between six-month progression-free survival and 12-month overall survival end points for Phase II trials in patients with glioblastoma multiforme. Neuro. Oncol.9, 29–38 (2007).
   PubMed Web of Science ®Google Scholar
• Osoba D, Aaronson NK, Muller M et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J. Neurooncol.34, 263–278 (1997).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Fiorentino MV. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest.14, 551–559 (1996).
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res.57, 1419–1424 (1997).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J. Clin. Oncol.22, 4779–4786 (2004).
   PubMed Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol.20, 1383–1388 (2002).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Basso U, Reni M et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a Phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J. Clin. Oncol.22, 1598–1604 (2004).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Hess KR, Yung WK et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol.21, 2305–2311 (2003).
   PubMed Web of Science ®Google Scholar
• Cokgor I, Friedman HS, Friedman AH. Chemotherapy for adults with malignant glioma. Cancer Invest.17, 264–272 (1999).
   PubMed Web of Science ®Google Scholar
• Franceschi E, Omuro AM, Lassman AB et al. Salvage temozolomide for prior temozolomide responders. Cancer104, 2473–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Perry J, Mason W, Belanger K et al. The Temozolomide RESCUE study: a Phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. Clin. Oncol.26(Suppl. 15) (2008) (Abstract 2010).
   Google Scholar
• Brandes AA, Tosoni A, Franceschi E et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a Phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother. Pharmacol.(Epub ahead of print) (2009).
   Google Scholar
• Fabrini MG, Silvano G, Lolli I et al. A multi-institutional Phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J. Neurooncol.92(1), 79–86 (2008).
   PubMedGoogle Scholar
• Scoccianti S, Detti B, Sardaro A et al. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs19, 613–620 (2008).
   PubMedGoogle Scholar
• Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol.22, 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• Franceschi E, Cavallo G, Lonardi S et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre Phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br. J. Cancer96(7), 1047–1051 (2007).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst.97, 880–887 (2005).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353, 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol.27, 1268–1274 (2009).
   PubMed Web of Science ®Google Scholar
• de Groot JF, Gilbert MR, Aldape K et al. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J. Neurooncol.90, 89–97 (2008).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res.13, 1253–1259 (2007).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25, 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer112, 2267–2273 (2008).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Prados MD, Wen PY et al. A Phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J. Clin. Oncol.26(Suppl.) (2008) (Abstract 2010b).
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.27(5), 740–745 (2008).
   PubMedGoogle Scholar
• Levin VA, Crafts DC, Norman DM et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J. Neurosurg.47, 329–335 (1977).
   PubMed Web of Science ®Google Scholar
• Norden AD, Drappatz J, Muzikansky A et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J. Neurooncol.92, 149–155 (2009).
   PubMed Web of Science ®Google Scholar
• Chen W, Delaloye S, Silverman DH et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with 18Ffluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol.25, 4714–4721 (2007).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11, 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Norden AD, Drappatz J, Ciampa AS et al. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro. Oncol.11, 92–95 (2009).
   PubMedGoogle Scholar
• Stupp R, Goldbrunner R, Neyns B et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J. Clin. Oncol.25(Supp.18) (2007) (Abstract 2000).
   Google Scholar
• Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol.26, 5610–5617 (2008).
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol.26, 4659–4665 (2008).
   PubMed Web of Science ®Google Scholar
• Jefferies S, Burton K, Jones P, Burnet N. Interpretation of early imaging after concurrent radiotherapy and temozolomide for glioblastoma. Clin. Oncol. (R. Coll. Radiol.)19(Supp.), 33 (2007).
   Google Scholar
• Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol.23, 5294–5304 (2005).
   PubMed Web of Science ®Google Scholar